Thermo Fisher to develop, manufacture next-gen immunotherapy – The Science Board

Posted by on June 11, 2020 1:44 am
Tags:
Categories: Crispr Articles

Source: Thermo Fisher to develop, manufacture next-gen immunotherapy – The Science Board

Under the agreement, PharmAbcine will use Thermo Fisher’s Quick to Clinic integrated service offering, a program that accelerates drug development for investigational new drug (IND) submissions for phase I clinical trials.

PMC-309 is a fully human monoclonal antibody (immunoglobulin G) that targets the epitope of human V-domain immunoglobulin suppressor of T-cell activation (VISTA) that is primarily expressed on myeloid-derived suppressor cells. Inhibition of VISTA-positive immunosuppression is a promising immunotherapeutic strategy and an alternative to PD1/PDL1 targeting immuno-oncology drugs.

The drug will be developed at Thermo Fisher’s site in Princeton, NJ, and PharmAbcine plans to initiate IND-enabling studies this year and submit global IND in 2021.

Related Reading

Copyright © 2020 scienceboard.net

Published at Wed, 10 Jun 2020 23:36:15 +0000

< Immunotherapy Today home